TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22718223

Group type: EXPERIMENTAL
Intervention: Baseline fasting glucose level of 6.1 mmol/L or more
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Baseline pain-related disability
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: EuroQol (EQ)-index
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: EuroQol (EQ)-visual analogue scale
Number of subjects: 250
Study: 22115000

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system patch wear times (9, 10, 11, and 12 hours per day)
Number of subjects: 26
Study: 19190206

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (glucantime)
Number of subjects: 0
Study: 17041083

Group type: EXPERIMENTAL
Intervention: Sequence A: 0.016-inch NiTi, 0.018 x 0.025-inch NiTi, 0.019 x 0.025-inch SS
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Sequence B: 0.016-inch NiTi, 0.016-inch SS, 0.020-inch SS, 0.019 x 0.025-inch SS
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Sequence C: 0.016 x 0.022-inch Cu NiTi, 0.019 x 0.025-inch CuNiTi, 0.019 x 0.025-inch SS
Number of subjects: 154
Study: 14652119

Group type: COMPARATOR
Intervention: LMA (standard Laryngeal Mask Airway)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PLMA (LMA-ProSeal)
Number of subjects: 60
Study: 10722781

Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Noncarbohydrate Control (PL)
Number of subjects: 10
Study: 9114686

Group type: EXPERIMENTAL
Intervention: Polyglactin sutures
Number of subjects: 190

Group type: COMPARATOR
Intervention: Plain catgut sutures
Number of subjects: 190

Group type: COMPARATOR
Intervention: Skin tapes
Number of subjects: 190
Study: 1589701

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg) plus amiloride (5 mg)
Number of subjects: 100
Study: 3897071

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prazosin 2 mg twice a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31513671

Group type: EXPERIMENTAL
Intervention: Eccentric overload (EOL) exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Traditional weightlifting (TW) exercise
Number of subjects: 10
Study: 29573567

Group type: EXPERIMENTAL
Intervention: VAD therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard heart failure therapy (with or without sildenafil, nitrates, or endothelin receptor antagonists)
Number of subjects: 24
Study: 26759138

Group type: EXPERIMENTAL
Intervention: Daily low-dose aspirin (81 mg/day) plus folic acid (400 mcg/day)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Placebo plus folic acid (400 mcg/day)
Number of subjects: 1228
Study: 25305054

Group type: EXPERIMENTAL
Intervention: Non-contact care with four physical 10-minute consultations/year and three non-physical 10-minute consultations/year
Number of subjects: 597

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 597
Study: 22730950

Group type: EXPERIMENTAL
Intervention: Couple CARE for Parents (CCP)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Becoming a Parent Program (BAP)
Number of subjects: 250
Study: 19182989

Group type: EXPERIMENTAL
Intervention: Telephone counseling and home telemonitoring (Thin-Link(R) home telemonitoring scale and biweekly counseling for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed-start group (no immediate intervention)
Number of subjects: 0
Study: 17478360

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 106
Study: 14748874

Group type: EXPERIMENTAL
Intervention: Continuous somatostatin infusion for 12 hours starting 30 minutes before ERCP
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Bolus intravenous injection of somatostatin at the time of cannulation
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Somatostatin groups (both continuous infusion and bolus)
Number of subjects: 372
Study: 12073055

Group type: EXPERIMENTAL
Intervention: Radiotherapy with the Nijmegen technique (4 fractions of 6 Gy directed to the macular area)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 63
Study: 9642631

Group type: EXPERIMENTAL
Intervention: Children of one obese parent
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Children of two obese parents
Number of subjects: 886

Group type: COMPARATOR
Intervention: Children of normal weight parents
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Group B (obesity onset at mean age of 5.3 +/- 2.6 years)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Group A (obesity always present)
Number of subjects: 886
Study: 7877160

Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE) positions
Number of subjects: 0
Study: 2713259

Group type: EXPERIMENTAL
Intervention: Diphencyprone
Number of subjects: 17

Group type: COMPARATOR
Intervention: Tretinoin gel (Retin A)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diphencyprone (after 20 weeks of tretinoin)
Number of subjects: 17
Study: 1100302

Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate (DP) intravenous administration at dosages ranging from 0.05 to 2.0 mg/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: 4 mg/ml parenteral solution of DP
Number of subjects: 18

Group type: COMPARATOR
Intervention: Experimental high potency preparation of 24 mg/ml
Number of subjects: 18
Study: 30894240

Group type: EXPERIMENTAL
Intervention: DBT skills group (DBT-SG)
Number of subjects: 17
Study: 28431538

Group type: EXPERIMENTAL
Intervention: Flexible cystoscope (Group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Rigid ureteroscope (Group B)
Number of subjects: 300
Study: 26154723

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 39
Study: 24522306

Group type: EXPERIMENTAL
Intervention: Oral polio vaccine (OPV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Real time PCR for non polio EV
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group with pre-vaccination blood sample (BS)
Number of subjects: 50
Study: 22122960

Group type: EXPERIMENTAL
Intervention: Combination of beta-carotene, vitamins C and E, and magnesium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control)
Number of subjects: 0
Study: 17700397

Group type: EXPERIMENTAL
Intervention: Canrenone (up to 50 mg/day)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 467
Study: 15868595

Group type: EXPERIMENTAL
Intervention: Cholecystokinin-octapeptide (CCK)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 38
Study: 11998815

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 46
Study: 9673807

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 20 mg
Number of subjects: 2395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2395

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 10 mg
Number of subjects: 2395

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray (both dosages)
Number of subjects: 2395
Study: 7633535

Group type: EXPERIMENTAL
Intervention: High-cost antibiotics (amoxicillin plus clavulanate potassium, cefaclor, or cefixime) for persistent middle ear effusions
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Oral decongestants (alone or in combination with other therapy) at the 6-week visit
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Referral for ventilating tube surgery at the 9-week visit
Number of subjects: 66

Group type: COMPARATOR
Intervention: Management of recurrent episodes of acute otitis media
Number of subjects: 66
Study: 2755214

Group type: EXPERIMENTAL
Intervention: Potassium alone (2 g potassium chloride daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Potassium and magnesium combined supplementation (2 g potassium and 1 g magnesium daily)
Number of subjects: 10
Study: 329292

Group type: EXPERIMENTAL
Intervention: Baclofen (para-chlorphenyl-GABA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31642588

Group type: EXPERIMENTAL
Intervention: Open-flap approach
Number of subjects: 36

Group type: COMPARATOR
Intervention: Flapless approach
Number of subjects: 36
Study: 29231588

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding therapy applied at bilateral Tianshu (ST 25), Changqiang (GV 1), bilateral Chengshan (BL 57) and Tigangxue (Extra), once a week for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medication with 0.2% nitroglycerin ointment, applied externally on the wound, twice daily for 4 weeks.
Number of subjects: 60
Study: 26334610

Group type: EXPERIMENTAL
Intervention: Distributed practice (12 repeated virtual mastoidectomies with practice blocks spaced in time)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Massed practice (12 repeated virtual mastoidectomies all in 1 day)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Simulator-integrated tutoring during the first 5 sessions
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nontutored participants in the distributed practice group
Number of subjects: 43
Study: 23715924

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (300 mg magnesium as citrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21515290

Group type: EXPERIMENTAL
Intervention: Metoprolol monotherapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combined metoprolol and felodipin therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no medications)
Number of subjects: 46
Study: 18024955

Group type: EXPERIMENTAL
Intervention: Betamethasone gel
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lidocaine jelly
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 17059782

Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant chemotherapy
Number of subjects: 864

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 864
Study: 15120888

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 2073
Study: 12360593

Group type: EXPERIMENTAL
Intervention: Atenolol (76.9 +/- 6.6 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trimetazidine (60 mg/day)
Number of subjects: 50
Study: 9706829

Group type: EXPERIMENTAL
Intervention: ACE-inhibitors started within the first day after acute myocardial infarction and continued for 4 to 6 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE-inhibitors for patients with LVD.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE-inhibitors for patients without evidence of LVD.
Number of subjects: 0
Study: 7654644

Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg 36 h before gemeprost)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Laminaria tent (medium-sized, inserted 12 h before gemeprost)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 62

Group type: COMPARATOR
Intervention: Laminaria tent
Number of subjects: 62
Study: 2654350

Group type: EXPERIMENTAL
Intervention: Vitamin E (free alpha-tocopherol) administered parenterally and later orally at pharmacologic serum levels (5 mg/dl)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Vitamin E (free alpha-tocopherol) administered for greater than or equal to 8 days
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Vitamin E (free alpha-tocopherol)
Number of subjects: 755
Study: 901851

Group type: EXPERIMENTAL
Intervention: Anxiety Group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pleasant Group
Number of subjects: 40
Study: 30701691

Group type: EXPERIMENTAL
Intervention: VF biofeedback
Number of subjects: 19

Group type: COMPARATOR
Intervention: ssEMG biofeedback
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mixed biofeedback (VF phase 1, ssEMG phase 2)
Number of subjects: 19
Study: 28729151

Group type: EXPERIMENTAL
Intervention: Standard-dose pembrolizumab (2 mg/kg) plus reduced-dose ipilimumab (1 mg/kg) every 3 weeks for four doses, followed by pembrolizumab (2 mg/kg) every 3 weeks for up to 2 years or until disease progression or intolerable toxicity.
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Standard-dose pembrolizumab plus reduced-dose ipilimumab
Number of subjects: 153
Study: 25671796

Group type: EXPERIMENTAL
Intervention: DASH eating plan plus physical activity
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 23822902

Group type: EXPERIMENTAL
Intervention: Lucerne hay cubes at 0.4 M
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Lucerne hay cubes at 0.8 M
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Lucerne hay cubes at 1.2 M
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Lucerne hay cubes at 1.6 M
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Total energy recovery including heat production at varying DMI levels
Number of subjects: 4
Study: 21858972

Group type: EXPERIMENTAL
Intervention: Intraoperative anastomotic air testing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group without air testing
Number of subjects: 60
Study: 19833688

Group type: EXPERIMENTAL
Intervention: Urine sampling kit for partner notification arm
Number of subjects: 200

Group type: COMPARATOR
Intervention: Contact slips (swab testing arm)
Number of subjects: 200
Study: 17112806

Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg twice on the first day and 200 mg twice on the second day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg once daily for 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (20 microg/kg intravenous alfentanil without pretreatment)
Number of subjects: 12
Study: 15253849

Group type: EXPERIMENTAL
Intervention: Real qi therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11743061

Group type: EXPERIMENTAL
Intervention: Diet-plus-exercise program
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Diet-only program
Number of subjects: 264

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 264
Study: 9225710

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 8477560

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg moxisylyte
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg moxisylyte
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg moxisylyte
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3307093

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropins (HCG, 5,000 IU I.M. twice per week)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30950703

Group type: EXPERIMENTAL
Intervention: Head-lift exercise (HLE)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Recline exercise (RE)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both HLE and RE
Number of subjects: 27
Study: 30572894

Group type: EXPERIMENTAL
Intervention: 4 g krill oil powder
Number of subjects: 35

Group type: COMPARATOR
Intervention: 4 g placebo
Number of subjects: 35
Study: 27855089

Group type: EXPERIMENTAL
Intervention: HPV self-sampling (arm A)
Number of subjects: 834

Group type: COMPARATOR
Intervention: Papanicolaou (Pap) testing (arm B)
Number of subjects: 834
Study: 25124503

Group type: EXPERIMENTAL
Intervention: Parental involvement in children's anxiety treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-involved mothers
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (involved and not involved)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Self-reported parental efficacy and observed negativity
Number of subjects: 54
Study: 21905086

Group type: EXPERIMENTAL
Intervention: tolterodine 4 mg long‐acting (LA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 19452332

Group type: EXPERIMENTAL
Intervention: Chemomechanical method (Carisolv)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional rotary instruments
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 120
Study: 17092965

Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg + placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg + pindolol 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg + ketanserin 50 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 15642064

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) mouth rinse for 15 seconds
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) mouth rinse for 30 seconds
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) mouth rinse for 60 seconds
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 12552952

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of 5-FU for 5 days at a dose of 320 mg/m2 (CIV group, n = 6)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bolus intravenous injection of 5-FU for 5 days at a dose of 320 mg/m2 (bolus group, n = 8)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated controls (n = 16)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5-FU-resistant group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5-FU-sensitive group
Number of subjects: 30
Study: 9585021

Group type: EXPERIMENTAL
Intervention: Fecal occult blood test (FOBT) screening
Number of subjects: 3
Study: 7815748

Group type: EXPERIMENTAL
Intervention: r‐HuEPO 6,000 IU, subcutaneously once a week for up to 9 weeks (group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: r‐HuEPO 9,000 IU, subcutaneously once a week for up to 9 weeks (group II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (both groups)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 2576666

Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg once daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 43
Study: 1059499

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside and thioguanine
Number of subjects: 326

Group type: COMPARATOR
Intervention: Cytosine arabinoside alone
Number of subjects: 326
Study: 31227287

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 26215773

Group type: EXPERIMENTAL
Intervention: Reinflation after early release of tourniquet
Number of subjects: 206

Group type: COMPARATOR
Intervention: Early release (deflation) group
Number of subjects: 206
Study: 25306520

Group type: EXPERIMENTAL
Intervention: Silbroncho (silicon DLTs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Broncho‐Cath (PVC DLTs)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 23788085

Group type: EXPERIMENTAL
Intervention: pPCI
Number of subjects: 95
Study: 22926838

Group type: EXPERIMENTAL
Intervention: Clomifene citrate plus metformin
Number of subjects: 172

Group type: COMPARATOR
Intervention: Clomifene citrate plus placebo
Number of subjects: 172
Study: 19927695

Group type: EXPERIMENTAL
Intervention: Gaps-In-Noise (GIN) test
Number of subjects: 72
Study: 17851827

Group type: EXPERIMENTAL
Intervention: Amine fluoride gel (4000 ppm F)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 135
Study: 15333056

Group type: EXPERIMENTAL
Intervention: Educational mailers (2 packets mailed approximately 3 months apart)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care for hypertension
Number of subjects: 312
Study: 16208800

Group type: EXPERIMENTAL
Intervention: PC 7000 toothbrush (Oral‐B ProfessionalCare 7000)
Number of subjects: 92

Group type: COMPARATOR
Intervention: SBP toothbrush (Crest SpinBrush Pro)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both toothbrushes
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Safety examinations
Number of subjects: 92
Study: 10695793

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg once a day for 3 days
Number of subjects: 113

Group type: COMPARATOR
Intervention: Tinidazole 50 mg/kg single dose
Number of subjects: 113
Study: 8670601

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SSZ) 2.0 g/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 1662583

Group type: EXPERIMENTAL
Intervention: Nebulizer with 99mTc‐labelled colloidal human serum albumin (0.05 mg, 37 MBq)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nebulizer with increased 99mTc activity (92 MBq)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nebulizer particle size measurement
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nebulizer mass and radionuclide output measurement
Number of subjects: 9
Study: 6751018

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31718728

Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 50

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 50
Study: 29103368

Group type: EXPERIMENTAL
Intervention: TRIP implementation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study: 26911887

Group type: EXPERIMENTAL
Intervention: 100 kV with additional tin filtration, 150mAs, 192x0.6-mm slice collimation
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard low-dose protocol (100 kV, 50mAs, 128×0.6-mm slice collimation)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 100 kV with additional tin filtration
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard low-dose protocol
Number of subjects: 129